2026年德山历年年报/社会责任报告/ESG报告合集（共9套打包）

1、9M 2025 sales updateOctober 30,2025DisclaimerThis presentation contains forward-looking statements,which offer no guarantee with regard to future performance.These statements are made on the basis of。

2、August 7,2025H1 2025 resultsDisclaimerThis presentation contains forward-looking statements,which offer no guarantee with regard to future performance.These statements are made on the basis 。

3、Integrated Annual Report 2024Pioneering access for patientsIntegrated Annual Report 2024OverviewFinancial ReportESG DisclosuresBusiness ReportGovernance,Compensation&RiskTable of contents04Sandoz。

4、Financial ReportOverviewFinancial ReportESG DisclosuresBusiness ReportGovernance,Compensation&RiskIntegrated Annual Report 20249293 Performance overview99 Consolidated financial statements of the。

5、FY 2024 resultsMarch 5,20252This presentation contains forward-looking statements,which offer no guarantee with regard to future performance.These statements are made on the basis of managements view。

6、Corporate Governance ReportOverviewFinancial ReportESG DisclosuresBusiness ReportGovernance,Compensation&RiskIntegrated Annual Report 20244344 Corporate Governance framework44 ESG Governance45 Gr。

7、Q1 2025 sales updateApril 30,20252This presentation contains forward-looking statements,which offer no guarantee with regard to future performance.These statements are made on the basis of management。

8、Compensation Report63 Shareholder letter from the Chair of the Human Capital&ESG Committee64 Executive Committee and Board compensation at a glance65 Executive Committee compensation75 Board of D。

9、Integrated Annual Report 2023Pioneering access for patientsOur Vision is to be the worlds leading and most valued biosimilars and generics company.Read more/Page 07Pioneering access for patients.Our 。